Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 Study of ACTR707, an Autologous T Cell Product, in Combination With Rituximab, in Subjects With Relapsed or Refractory CD20+ B Cell Lymphoma

Trial Profile

Phase 1 Study of ACTR707, an Autologous T Cell Product, in Combination With Rituximab, in Subjects With Relapsed or Refractory CD20+ B Cell Lymphoma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 03 Jan 2019

At a glance

  • Drugs ACTR707 (Primary) ; Rituximab (Primary) ; Cyclophosphamide; Fludarabine
  • Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions; First in man
  • Sponsors Unum Therapeutics
  • Most Recent Events

    • 03 Jan 2019 According to an Unum Therapeutics media release, dose escalation completion, initiation of dose expansion and read outs from both the Phases are anticipated in 2019.
    • 12 Dec 2018 According to an Unum Therapeutics media release, based on the data of these two levels, enrollment in the dose level 3 is progressing as planned.
    • 04 Dec 2018 Results (n=6), assessing preliminary clinical findings, presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top